Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Q3 2025 value amounting to -$1.9 million.

  • Cumberland Pharmaceuticals' Net Income towards Common Stockholders fell 2681.1% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 6922.09%. This contributed to the annual value of -$6.4 million for FY2024, which is 178.41% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$1.9 million for Q3 2025, which was down 2681.1% from -$735207.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $1.2 million for Q1 2025, and its period low was -$6.3 million during Q4 2023.
  • Over the past 4 years, Cumberland Pharmaceuticals' median Net Income towards Common Stockholders value was -$735207.0 (recorded in 2025), while the average stood at -$795506.2.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 120425.22% in 2024, then soared by 16560.85% in 2025.
  • Over the past 4 years, Cumberland Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $503318.0 in 2021, then crashed by 1352.09% to -$6.3 million in 2023, then soared by 69.82% to -$1.9 million in 2024, then fell by 2.49% to -$1.9 million in 2025.
  • Its Net Income towards Common Stockholders was -$1.9 million in Q3 2025, compared to -$735207.0 in Q2 2025 and $1.2 million in Q1 2025.